Exelixis Inc EXEL:NASDAQ

Last Price$17.70NASDAQ Previous Close - Last Trade as of 3:58PM ET 5/24/22

Today's Change-0.05(0.28%)
Bid (Size)$17.70 (141)
Ask (Size)$18.01 (99)
Day Low / High$17.49 - 17.83
Volume2.7 M

View Biotechnology IndustryPeer Comparison as of 05/24/2022


Exelixis Inc ( NASDAQ )

Price: $17.70
Change: -0.05 (0.28%)
Volume: 2.7 M
3:58PM ET 5/24/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Halozyme Therapeutics Inc ( NASDAQ )

Price: $44.82
Change: +0.49 (1.11%)
Volume: 826.7 K
3:58PM ET 5/24/2022

Novavax Inc ( NASDAQ )

Price: $46.54
Change: -4.86 (9.46%)
Volume: 3.4 M
3:58PM ET 5/24/2022

Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $33.80
Change: -2.25 (6.24%)
Volume: 782.9 K
3:58PM ET 5/24/2022

Read more news Recent News

Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
4:32PM ET 5/10/2022 MT Newswires

Exelixis (EXEL) reported late Tuesday Q1 non-GAAP earnings of $0.26 per diluted share, compared with $0.09 a year earlier. Analysts polled by Capital IQ...

-- Earnings Flash (EXEL) EXELIXIS Posts Q1 EPS $0.26, vs. Street Est of $0.23
4:09PM ET 5/10/2022 MT Newswires


-- Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $356M, vs. Street Est of $363.2M
4:09PM ET 5/10/2022 MT Newswires


Earnings Reaction History: Exelixis Inc, 45.5% Follow-Through Indicator, 5.4% Sensitive
12:22PM ET 5/10/2022 MT Newswires

Expected Earnings Release: 05/10/2022, After-hours Avg. Extended-Hours Dollar Volume: $7,478,822 Exelixis Inc (EXEL) is due to issue its quarterly earnings...

View all Commentary and Analysis

Exelixis: Becoming A Giant Pharma
11:20AM ET 5/18/2022 Seeking Alpha

Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2022 Results - Earnings Call Transcript
10:15PM ET 5/10/2022 Seeking Alpha

IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally
2:21PM ET 4/29/2022 Seeking Alpha

Finding Value Stocks Trading At A Discount
5:43AM ET 4/28/2022 Seeking Alpha

Company Profile

Business DescriptionExelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA. View company web site for more details
Address1851 Harbor Bay Parkway
Alameda, California 94502
Number of Employees484
Recent SEC Filing05/17/20224
President, Chief Executive Officer & DirectorMichael M. Morrissey
Executive Vice President-Business OperationsDana T. Aftab
Chief Financial Officer & Executive Vice PresidentChristopher J. Senner
Chief Scientific Officer & EVP-Scientific StrategyPeter Lamb

Company Highlights

Price Open$17.61
Previous Close$17.75
52 Week Range$15.50 - 24.69
Market Capitalization$5.7 B
Shares Outstanding320.7 M
SectorHealth Technology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings19.30
Earnings per Share$0.92
Beta vs. S&P 500N/A
Revenue$845.7 M
Net Profit Margin19.60%
Return on Equity13.77%

Analyst Ratings as of 04/14/2022

Consensus RecommendationConsensus Icon
Powered by Factset